Keywords: Presidio Pharma, Boehringer Ingelheim, Hepatitis C, Combination drug, PPI-668, Faldaprevir, BI207127, Research collaboration

Presidio Pharma inks deal with Boehringer Ingelheim for hep C combo

Article | 14 March 2013

Privately-held USA-based Presidio Pharmaceuticals has entered into a non-exclusive collaboration with family-owned German drug major Boehringer Ingelheim for a Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Boehringer Ingelheim

Presidio Pharmaceuticals

Go to company listing

Related Drugs

faldaprevir

PPI-668

BI207127

Go to drug listing